Identifying and addressing the toxicity of checkpoint inhibitors in lung cancer
Brahmer, J.R.
Clinical Advances in Hematology and Oncology H&o 14(3): 165-167
2016
ISSN/ISBN: 1543-0790 PMID: 27058029 Document Number: 686864
Document emailed within 1 workday
Related Documents
McArthur, H.L. 2016: Checkpoint inhibitors in breast cancer: hype or promise? Clinical Advances in Hematology and Oncology: H&o 14(6): 392-395Muro, K. 2016: Potentiality of Immune Checkpoint Inhibitors for Advanced Esophageal and Gastric Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 43(9): 1041-1047
Aphinyanaphongs, Y.; Fu, L.D.; Aliferis, C.F. 2013: Identifying unproven cancer treatments on the health web: addressing accuracy, generalizability and scalability Studies in Health Technology and Informatics 192: 667-671
Li, B.; Chan, H.Lam.; Chen, P. 2019: Immune Checkpoint Inhibitors: Basics and Challenges Current Medicinal Chemistry 26(17): 3009-3025
Trivedi, M.S.; Hoffner, B.; Winkelmann, J.L.; Abbott, M.E.; Hamid, O.; Carvajal, R.D. 2015: Programmed death 1 immune checkpoint inhibitors Clinical Advances in Hematology and Oncology: H&o 13(12): 858-868
Chen, W.J.Y.; Krul-Poel, Y.H.M.; Roth, C.; Labots, M.; van den Eertwegh, A.J.M.; Dreijerink, K.M.A. 2019: Endocrine side effects of checkpoint inhibitors Nederlands Tijdschrift Voor Geneeskunde 163
Jaafar, J.; Mavromati, M.; Philippe, J. 2018: Endocrinopathies induced by immune checkpoint inhibitors Revue Medicale Suisse 14(588-589): 34-38
Miyawaki, E.; Kenmotsu, H. 2018: Pneumonitis Induced by Immune Checkpoint Inhibitors Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(7): 1021-1026
Jørgensen, L.B.; Bastholt, L.; Yderstræde, K. 2017: Immune checkpoint inhibitors and endocrinological side effects Ugeskrift for Laeger 179(49)
Sullivan, R.J. 2019: The future of combination treatment with checkpoint inhibitors in melanoma Clinical Advances in Hematology and Oncology: H&o 17(2): 96-99
Fuse, M.; Yoshimura, K. 2017: The development status of the next-generation immune checkpoint inhibitors Nihon Rinsho. Japanese Journal of Clinical Medicine 75(2): 245-250
Inaba, H.; Ariyasu, H.; Kurimoto, C.; Iwakura, H.; Akamizu, T. 2018: Endocrine Organ Dysfunction with Immune-Checkpoint Inhibitors Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(7): 1031-1035
Webb, P.; Rice, T.W.; Cooksley, T. 2017: Problem-based review: Immune-mediated complications of 'Checkpoint Inhibitors' for the Acute Physician Acute Medicine 16(1): 21-24
Eto, M. 2017: New Treatment Options for Renal Cell Carcinoma - Efficacy and Safety of Immune Checkpoint Inhibitors Gan to Kagaku Ryoho. Cancer and ChemoTherapy 44(8): 667-673
Owada-Ozaki, Y.; Nishiyama, K.; Kobayashi, T.; Suzutani, T.; Suzuki, H. 2018: A Study of Biomarkers in Immuno-Oncology - Correlation between Gut Microbiome Composition and the Effects of Immune Checkpoint Inhibitors Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(9): 1234-1237
Cooling, L.L.; Sherbeck, J.; Mowers, J.C.; Hugan, S.L. 2017: Development of red blood cell autoantibodies following treatment with checkpoint inhibitors: a new class of anti-neoplastic, immunotherapeutic agents associated with immune dysregulation Immunohematology 33(1): 15-21
Chuma, J.; Okungu, V.; Ntwiga, J.; Molyneux, C. 2010: Towards achieving Abuja targets: identifying and addressing barriers to access and use of insecticides treated nets among the poorest populations in Kenya Bmc Public Health 10: 137
Cho, L.C.; Choy, H. 2004: Topoisomerase i inhibitors in the combined-modality therapy of lung cancer Oncology 18(7 Suppl 4: 29-39
Fukuoka, M. 2001: Role of topoisomerase i inhibitors in small-cell lung cancer Oncology 15(7 Suppl 8: 9-13
Krepela, E.; Procházka, J.; Kárová, B.; Cermák, J.; Roubková, H. 1997: Cathepsin B, thiols and cysteine protease inhibitors in squamous-cell lung cancer Neoplasma 44(4): 219-239